CytRx Corporation (CYTR) - Financial and Strategic SWOT Analysis Review

Date: May 3, 2016
Pages: 52
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C49085EBA50EN
Leaflet:

Download PDF Leaflet

CytRx Corporation (CYTR) - Financial and Strategic SWOT Analysis Review
CytRx Corporation (CYTR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

CytRx Corporation (CytRx) is a clinical state is a biopharmaceutical company focusing on the research and development of novel treatments for cancer. The company’s oncology based product mainly comprises its lead drug product candidate, aldoxorubicin (formerly INNO-206). Aldoxorubicin is a pro-drug of the commonly prescribed chemotherapeutic doxorubicin, designed to reduce adverse events by controlling release and preferentially targeting the tumor. Its other new albumin-binding drug conjugates are pre-clinical development. The company conducts its discovery and translational research at its new discovery laboratory located in Freiburg, Germany. The company has a strategic alliance with KTB Tumorforschungs GmbH. CytRx is headquartered in Los Angeles, California, the US.

The company focuses on advancing the development of novel treatments for various cancer indications. In lieu of this the company in October, 2014 set up new discovery laboratory, in Freiburg, Germany, to conducting discovery and translational research.

CytRx Corporation Key Recent Developments

Mar 11, 2016: CytRx Reports 2015 Financial Results
Jan 11, 2016: CytRx Appoints Olivia Ware as Chief Commercial Officer
Dec 10, 2015: CytRx Announces Settlement of the Consolidated Securities Class Action Lawsuit
Nov 03, 2015: CytRx Reports 2015 Third Quarter Financial Results
Aug 03, 2015: CytRx Reports 2015 Second Quarter Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company. - The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably. - Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance. - Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research. - Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

CytRx Corporation - Key Facts
CytRx Corporation - Key Employees
CytRx Corporation - Key Employee Biographies
CytRx Corporation - Major Products and Services
CytRx Corporation - History
CytRx Corporation - Company Statement
CytRx Corporation - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

CytRx Corporation - Business Description
CytRx Corporation - Corporate Strategy
CytRx Corporation - SWOT Analysis
SWOT Analysis - Overview
CytRx Corporation - Strengths
Strength - Lead Candidate: Aldoxorubicin
Strength - Focussed R&D Activities
Strength - Intellectual Property
CytRx Corporation - Weaknesses
Weakness - Reliance on Third-Parties
Weakness - History of Losses
Weakness - Lack of Marketed Products
CytRx Corporation - Opportunities
Opportunity - Orphan Drug Designations
Opportunity - Strong Portfolio of Cancer Treatment Pipeline
Opportunity - Growing Market for Cancer Treatments
Opportunity - New Pipeline
CytRx Corporation - Threats
Threat - Intense Competition
Threat - Uncertain R&D Outcomes
Threat - Stringent Government Regulations
CytRx Corporation - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

CytRx Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
CytRx Corporation, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
CytRx Corporation, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Mar 11, 2016: CytRx Reports 2015 Financial Results
Jan 11, 2016: CytRx Appoints Olivia Ware as Chief Commercial Officer
Dec 10, 2015: CytRx Announces Settlement of the Consolidated Securities Class Action Lawsuit
Nov 03, 2015: CytRx Reports 2015 Third Quarter Financial Results
Aug 03, 2015: CytRx Reports 2015 Second Quarter Financial Results
Jun 30, 2015: CytRx Unveils Novel LADR (Linker Activated Drug Release) Technology Platform
Jun 24, 2015: Cheryl Cohen, Former Medivation Chief Commercial Officer, Joins CytRx Board of Directors
May 01, 2015: CytRx Reports First Quarter 2015 Financial Results
Mar 11, 2015: Dr. Anita J. Chawla Joins CytRx Board of Directors to Add Additional Drug Commercialization Expertise in Oncology
Mar 10, 2015: CytRx Reports 2014 Financial Results

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

CytRx Corporation, Key Facts
CytRx Corporation, Key Employees
CytRx Corporation, Key Employee Biographies
CytRx Corporation, Major Products and Services
CytRx Corporation, History
CytRx Corporation, Subsidiaries
CytRx Corporation, Key Competitors
CytRx Corporation, Ratios based on current share price
CytRx Corporation, Annual Ratios
CytRx Corporation, Interim Ratios
CytRx Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
CytRx Corporation, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
CytRx Corporation, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

CytRx Corporation, Performance Chart (2011 - 2015)
CytRx Corporation, Ratio Charts
CytRx Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
CytRx Corporation, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016
Skip to top


Ask Your Question

CytRx Corporation (CYTR) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: